ReviewNature reviews. Clinical oncology2021
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.
Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Antibody-drug conjugates and immune checkpoint inhibitors in cancer treatment: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis.Nature communications · 2023Pooled it
- Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review.Frontiers in pharmacology · 2022Pooled it
- Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.Blood · 2021Trial
- Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management.Human vaccines & immunotherapeutics · 2026Review
- From HPV infection to cervical precancer: Molecular mechanisms, immune microenvironment and emerging technologies.Cellular and molecular life sciences : CMLS · 2026Review
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Innovative technologies and future perspectives in tumor microbiomics.Science China. Life sciences · 2026Review
- ALNCR.TNM as a Novel Prognostic Tool for Cancer Survival.Journal of cachexia, sarcopenia and muscle · 2026Article
- Nested Nanowell Arrays for High-Throughput Quantitative Analysis of Cytokines from Single Macrophages.ACS nano medicine · 2026Article
- Review
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- RECOMBINE identifies recurrent composite markers of cell types and states.Genome research · 2026Article
- PVAED: prior-guided variational autoencoders with diffusion denoising for interpretable single-cell representation learning.Briefings in bioinformatics · 2026Article
- Selective access to individual cells after assembling for advanced cell-cell interaction studies.Journal of nanobiotechnology · 2026Article
- Navigating the Landscape of Cytometry-Based Single-Cell Proteomics: Quantification, Annotation, and Resources.International journal of molecular sciences · 2026Review
- Clustering single-cell multi-omics data via weighted distance penalty and adaptive consistent graph regularization.PLoS computational biology · 2026Article
- Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.Nature reviews. Clinical oncology · 2026Review
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advances in molecular biology, microfluidics and bioinformatics have empowered the study of thousands or even millions of individual cells from malignant tumours at the single-cell level of resolution. This high-dimensional, multi-faceted characterization of the genomic, transcriptomic, epigenomic and proteomic features of the tumour and/or the associated immune and stromal cells enables the dissection of tumour heterogeneity, the complex interactions between tumour cells and their microenvironment, and the details of the evolutionary trajectory of each tumour. Single-cell transcriptomics, the ability to track individual T cell clones through paired sequencing of the T cell receptor genes and high-dimensional single-cell spatial analysis are all areas of particular relevance to immuno-oncology. Multidimensional biomarker signatures will increasingly be crucial to guiding clinical decision-making in each patient with cancer. High-dimensional single-cell technologies are likely to provide the resolution and richness of data required to generate such clinically relevant signatures in immuno-oncology. In this Perspective, we describe advances made using transformative single-cell analysis technologies, especially in relation to clinical response and resistance to immunotherapy, and discuss the growing utility of single-cell approaches for answering important research questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.